These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 16737676)

  • 1. A fluorescence polarization-based assay for peptidyl prolyl cis/trans isomerase cyclophilin A.
    Liu Y; Jiang J; Richardson PL; Reddy RD; Johnson DD; Kati WM
    Anal Biochem; 2006 Sep; 356(1):100-7. PubMed ID: 16737676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isoform-specific inhibition of cyclophilins.
    Daum S; Schumann M; Mathea S; Aumüller T; Balsley MA; Constant SL; de Lacroix BF; Kruska F; Braun M; Schiene-Fischer C
    Biochemistry; 2009 Jul; 48(26):6268-77. PubMed ID: 19480458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of a real-time fluorescence monitoring system for high-throughput screening for prolyl isomerase inhibitors.
    Mori T; Itami S; Yanagi T; Tatara Y; Takamiya M; Uchida T
    J Biomol Screen; 2009 Apr; 14(4):419-24. PubMed ID: 19403925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and validation of a fluorescence polarization-based competitive peptide-binding assay for HLA-A*0201--a new tool for epitope discovery.
    Buchli R; VanGundy RS; Hickman-Miller HD; Giberson CF; Bardet W; Hildebrand WH
    Biochemistry; 2005 Sep; 44(37):12491-507. PubMed ID: 16156661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transgenic mice overexpressing cyclophilin A are resistant to cyclosporin A-induced nephrotoxicity via peptidyl-prolyl cis-trans isomerase activity.
    Hong F; Lee J; Piao YJ; Jae YK; Kim YJ; Oh C; Seo JS; Yun YS; Yang CW; Ha J; Kim SS
    Biochem Biophys Res Commun; 2004 Apr; 316(4):1073-80. PubMed ID: 15044094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation, characterization and refolding in vitro of a recombinant human cyclophilin A mutant: effect of a single Pro/Ser substitution on cyclophilin A structure and properties.
    Xu LR; Yan X; Luo M; Guan YX; Yao SJ
    Biotechnol Prog; 2008; 24(2):302-10. PubMed ID: 18333624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategy for discovering chemical inhibitors of human cyclophilin a: focused library design, virtual screening, chemical synthesis and bioassay.
    Li J; Zhang J; Chen J; Luo X; Zhu W; Shen J; Liu H; Shen X; Jiang H
    J Comb Chem; 2006; 8(3):326-37. PubMed ID: 16677001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The molecular replacement solution and X-ray refinement to 2.8 A of a decameric complex of human cyclophilin A with the immunosuppressive drug cyclosporin A.
    Pflügl GM; Kallen J; Jansonius JN; Walkinshaw MD
    J Mol Biol; 1994 Dec; 244(4):385-409. PubMed ID: 7990129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclophilin A: potential functions and therapeutic target for human cancer.
    Obchoei S; Wongkhan S; Wongkham C; Li M; Yao Q; Chen C
    Med Sci Monit; 2009 Nov; 15(11):RA221-32. PubMed ID: 19865066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Aspergillus niger cypA gene encodes a cyclophilin that mediates sensitivity to the immunosuppressant cyclosporin A.
    Derkx PM; Madrid SM
    Mol Genet Genomics; 2001 Dec; 266(4):527-36. PubMed ID: 11810223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of dual inhibitors targeting both HIV-1 capsid and human cyclophilin A to inhibit the assembly and uncoating of the viral capsid.
    Li J; Tan Z; Tang S; Hewlett I; Pang R; He M; He S; Tian B; Chen K; Yang M
    Bioorg Med Chem; 2009 Apr; 17(8):3177-88. PubMed ID: 19328002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computational insight into small molecule inhibition of cyclophilins.
    Sambasivarao SV; Acevedo O
    J Chem Inf Model; 2011 Feb; 51(2):475-82. PubMed ID: 21194235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A fluorescence polarization based Src-SH2 binding assay.
    Lynch BA; Loiacono KA; Tiong CL; Adams SE; MacNeil IA
    Anal Biochem; 1997 Apr; 247(1):77-82. PubMed ID: 9126374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Solution structure of the cyclosporin A/cyclophilin complex by NMR.
    Thériault Y; Logan TM; Meadows R; Yu L; Olejniczak ET; Holzman TF; Simmer RL; Fesik SW
    Nature; 1993 Jan; 361(6407):88-91. PubMed ID: 8421500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crystal structures of cyclophilin A complexed with cyclosporin A and N-methyl-4-[(E)-2-butenyl]-4,4-dimethylthreonine cyclosporin A.
    Ke H; Mayrose D; Belshaw PJ; Alberg DG; Schreiber SL; Chang ZY; Etzkorn FA; Ho S; Walsh CT
    Structure; 1994 Jan; 2(1):33-44. PubMed ID: 8075981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oligopeptide cyclophilin inhibitors: a reassessment.
    Schumann M; Jahreis G; Kahlert V; Lücke C; Fischer G
    Eur J Med Chem; 2011 Nov; 46(11):5556-61. PubMed ID: 21963115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-based design, synthesis, and biological evaluation of novel inhibitors of human cyclophilin A.
    Guichou JF; Viaud J; Mettling C; Subra G; Lin YL; Chavanieu A
    J Med Chem; 2006 Feb; 49(3):900-10. PubMed ID: 16451056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A rapid, homogeneous, fluorescence polarization binding assay for peroxisome proliferator-activated receptors alpha and gamma using a fluorescein-tagged dual PPARalpha/gamma activator.
    Seethala R; Golla R; Ma Z; Zhang H; O'Malley K; Lippy J; Cheng L; Mookhtiar K; Farrelly D; Zhang L; Hariharan N; Cheng PT
    Anal Biochem; 2007 Apr; 363(2):263-74. PubMed ID: 17335769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovering potent small molecule inhibitors of cyclophilin A using de novo drug design approach.
    Ni S; Yuan Y; Huang J; Mao X; Lv M; Zhu J; Shen X; Pei J; Lai L; Jiang H; Li J
    J Med Chem; 2009 Sep; 52(17):5295-8. PubMed ID: 19691347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclophilin A inhibition: targeting transition-state-bound enzyme conformations for structure-based drug design.
    Nagaraju M; McGowan LC; Hamelberg D
    J Chem Inf Model; 2013 Feb; 53(2):403-10. PubMed ID: 23312027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.